A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy

A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study.

The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.

Major Inclusion Criteria:

• BMI: 27 to 45 kg/m2
• Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator
• Stable life-style, i.e. diet & physical activity, as determined by the Investigator
• Stable metformin daily dose ≥1000 mg for at least 3 months
• Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%